Ibrutinib (PCI-32765) is a potent, irreversible covalent BTK inhibitor. It affects BCR and NF-κB signaling pathways by covalently binding to Cys-481 of BTK, effectively inhibiting tumor cell proliferation and inducing apoptosis.
Ibrutinib (PCI-32765) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Ibrutinib (PCI-32765) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.